Assessment of Inhibition of Biofilm Formation and Plaque Bacterial Count of Fluoride Varnish Containing Chlorhexidine and Cetylpyridinium Chloride Versus Conventional Fluoride Varnish

NCT ID: NCT04254835

Last Updated: 2020-02-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-01

Study Completion Date

2020-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Two different Fluoride varnish systems(Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride (CPC) and conventional fluoride) will be applied to high caries risk patients to assess their clinical effects on plaque accumulation and plaque bacterial count .

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Preoperative steps:

* The diagnostic chart will be filled including all data about the patient's medical history, dental history, plaque assessment and plaque bacterial count.
* Scaling and polishing will be carried out for subjects.

clinical steps:

* Control Group: Conventional Fluoride varnish (Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein) will be applied on dry teeth in a thin layer, allowed to dry for 1 minute, and participants will be instructed to avoid rinsing after application, only spitting. Eating, drinking and brushing should be avoided for 1 hour after varnish application.
* Intervention Group: Varnish containing Fluoride, Chlorhexidine and Cetylpyridinium Chloride (Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein) will be applied on dry teeth in a thin layer, allowed to dry for 1 minute, and participants will be instructed to avoid rinsing after application, only spitting. Eating, drinking and brushing should be avoided for 1 hour after varnish application.

Each participant will be assessed for plaque retention using plaque index and Standardized photography and image analysis to disclosed dental plaque, and plaque bacterial count using culture media sensitive for mutans streptococci (MS) in the following intervals:

* Enrolment Baseline assessment
* First visit (2nd week)
* Second visit (4th week)
* Third visit (12th week)
* Fourth visit (24th week)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

High Caries Risk Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intervention group

Varnish containing Fluoride, Chlorhexidine and Cetylpyridinium Chloride (Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein) will applied to this group once at the beginning of the study.Plaque and bacterial count will be evaluated at intervals 2 weeks,4 weeks,12 weeks, and 24 weeks.

Group Type EXPERIMENTAL

Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein

Intervention Type DRUG

Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride

control group

Varnish containing Fluoride (Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein). will applied to this group once at the beginning of the study.

Plaque and bacterial count will be evaluated at intervals 2 weeks,4 weeks,12 weeks, and 24 weeks.

Group Type ACTIVE_COMPARATOR

Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein

Intervention Type DRUG

Conventional Fluoride varnish

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein

Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride

Intervention Type DRUG

Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein

Conventional Fluoride varnish

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with good general state of health.

* No signs of periodontitis.
* Patients had a recorded high bacterial count after caries risk assessment.
* No antibiotic treatment within 1 month prior to the start of the trial.
* No current medication with anti-inflammatory drugs.
* No use of antiseptic mouth rinses.
* Non-smokers.

Exclusion Criteria

* Patients with disabilities, systemic disease or severe medical conditions.

* Patients with severe or active periodontal disease.
* Antibiotic treatment within 1 month prior to the start of the trial.
* Current medication with anti-inflammatory drugs.
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hadeer Hesham Mohamed

Principle Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of dentistry Cairo Universty

Giza, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hadeer H Mohamed

Role: CONTACT

01015779373 ext. 00202

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Amir I Hafez, Associate Professor

Role: primary

+201100001278 ext. 00202

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

221091

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy Of A PVP-I Fluoride Varnish
NCT03082196 COMPLETED PHASE2